The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients
Open accessAbstract
Akt/PKB is a serine/threonine protein kinase that regulates cell cycle progression, apoptosis and growth factor mediated cell survival in association with tyrosine kinase receptors. The protein is a downstream effector of erbB-2 with implications in breast cancer progression and drug resistance in vitro. We aimed to examine the role of Akt-1 in breast cancer patients, by determining whether the expression (Akt-1) and/or activation (pAkt) were related to prognostic markers and survival. The expression of erbB-2, heregulin beta 1 and Bcl-2 was also assessed by flow cytometry or immunohistochemistry. This study comprised 93 patients, aged <50 who were treated with tamoxifen and/or goserelin. We found that pAkt was associated with lower S-phase fraction (P=0.001) and the presence of heregulin beta 1-expressing stromal cells (P=0.017). Neither Akt-1 nor pAkt was related with other factors. Tumour cells-derived heregulin beta 1 was found mainly in oestrogen receptor negative (P=0.026) and node negative (P=0.005) cases. Survival analysis revealed that pAkt positive patients were more prone to relapse with distant metastasis, independently of S-phase fraction and nodal status (multivariate analysis; P=0.004). The results suggest that activation of Akt may have prognostic relevance in breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation
COFFER, P. J., JIN, J., & WOODGETT, J. R. (1998) · Biochemical Journal · doi:10.1042/bj3350001 · Cited by 1,067
Role of Translocation in the Activation and Function of Protein Kinase B
Andjelkovic, M., Alessi, D. R., Meier, R., Fernandez, A., Lamb, N. J. C., Frech, M., Cron, P., Cohen, P., Lucocq, J. M., & Hemmings, B. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.50.31515 · Cited by 1,051
Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α
Campbell, R. A., Bhat-Nakshatri, P., Patel, N. M., Constantinidou, D., Ali, S., & Nakshatri, H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010840200 · Cited by 968
Identification of Heregulin, a Specific Activator of p185 erbB2
Holmes, W. E., Sliwkowski, M. X., Akita, R. W., Henzel, W. J., Lee, J., Park, J. W., Yansura, D., Abadi, N., Raab, H., Lewis, G. D., et al. (1992) · Science · doi:10.1126/science.256.5060.1205 · Cited by 962
The Regulation and Activities of the Multifunctional Serine/Threonine Kinase Akt/PKB
Kandel, E. S., & Hay, N. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4690 · Cited by 869
Molecular alterations of the AKT 2 oncogene in ovarian and breast carcinomas
Bellacosa, A., De Feo, D., Godwin, A. K., Bell, D. W., Cheng, J. Q., Altomare, D. A., Wan, M., Dubeau, L., Scambia, G., Masciullo, V., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640412 · Cited by 837
Cheng, J. Q., Ruggeri, B., Klein, W. M., Sonoda, G., Altomare, D. A., Watson, D. K., & Testa, J. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3636 · Cited by 793
Staal, S. P. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.14.5034 · Cited by 767
Basic Guide to the Mechanisms of Antiestrogen Action
Macgregor, J. I., & Jordan, V. C. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01358-9 · Cited by 694
Peles, E., Bacus, S. S., Koski, R. A., Lu, H. S., Wen, D., Ogden, S. G., Levy, R. B., & Yarden, Y. (1992) · Cell · doi:10.1016/0092-8674(92)90131-u · Cited by 524 · cited 1×
“…associated in vitro with induction of cell proliferation (Holmes et al, 1992; Aguilar et al, 1999), invasion (Hijazi et al, 2000), apoptosis (Daly et al, 1997), differentiation (Peles et al, 1992; Bacus et al, 1993) and inhibition of cell proliferation (Hamburger and Yoo, 1997; Xu et al, 1997).”
BackgroundMuise-Helmericks, R. C., Grimes, H. L., Bellacosa, A., Malstrom, S. E., Tsichlis, P. N., & Rosen, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.45.29864 · Cited by 511
Fibroblast-mediated acceleration of human epithelial tumor growth in vivo.
Camps, J. L., Chang, S. M., Hsu, T. C., Freeman, M. R., Hong, S. J., Zhau, H. E., von Eschenbach, A. C., & Chung, L. W. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.1.75 · Cited by 416
Phosphatidylinositol 3-Kinase Couples the Interleukin-2 Receptor to the Cell Cycle Regulator E2F
Brennan, P., Babbage, J. W., Burgering, B. M. T., Groner, B., Reif, K., & Cantrell, D. A. (1997) · Immunity · doi:10.1016/s1074-7613(00)80388-x · Cited by 404
Cellular and Molecular Pharmacology of Antiestrogen Action and Resistance
Clarke, R., Leonessa, F., Welch, J. N., & Skaar, T. C. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01479-0 · Cited by 397
Graff, J. R., Konicek, B. W., McNulty, A. M., Wang, Z., Houck, K., Allen, S., Paul, J. D., Hbaiu, A., Goode, R. G., Sandusky, G. E., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003145200 · Cited by 378
HER-2/neu Blocks Tumor Necrosis Factor-induced Apoptosis via the Akt/NF-κB Pathway
Zhou, B. P., Hu, M. C.-T., Miller, S. A., Yu, Z., Xia, W., Lin, S.-Y., & Hung, M.-C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.11.8027 · Cited by 371
Ruggeri, B. A., Huang, L., Wood, M., Cheng, J. Q., & Testa, J. R. (1998) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199802)21:2<81::aid-mc1>3.3.co;2-k · Cited by 329
Shekhar, M. P. V., Werdell, J., Santner, S. J., Pauley, R. J., & Tait, L. R. (2001) · PubMed · Cited by 327
Akt/Protein Kinase B Isoforms Are Differentially Regulated by Epidermal Growth Factor Stimulation
Okano, J.-I., Gaslightwala, I., Birnbaum, M. J., Rustgi, A. K., & Nakagawa, H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004112200 · Cited by 213
Prognostic value of bcl-2 expression in invasive breast cancer
Hellemans, P., van Dam, P., Weyler, J., van Oosterom, A., Buytaert, P., & Van Marck, E. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.338 · Cited by 187
Ahmed, N. N., Franke, T. F., Bellacosa, A., Datta, K., Gonzalez-Portal, M. E., Taguchi, T., Testa, J. R., & Tsichlis, P. N. (1993) · PubMed · Cited by 160
Ahmad, S., Singh, N., & Glazer, R. I. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00125-2 · Cited by 160
Perry, R. R., Kang, Y., & Greaves, B. (1995) · Annals of Surgical Oncology · doi:10.1007/bf02307030 · Cited by 158
Aguilar, Z., Akita, R. W., Finn, R. S., Ramos, B. L., Pegram, M. D., Kabbinavar, F. F., Pietras, R. J., Pisacane, P. I., Sliwkowski, M. X., & Slamon, D. J. (1999) · Oncogene · doi:10.1038/sj.onc.1202993 · Cited by 155
Mitsuuchi, Y., Johnson, S. W., Selvakumaran, M., Williams, S. J., Hamilton, T. C., & Testa, J. R. (2000) · PubMed · Cited by 137
Klinghoffer, R. A., Duckworth, B. C., Valius, M., Cantley, L. C., & Kazlauskas, A. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5905 · Cited by 136
Daly, J. M., Jannot, C. B., Beerli, R. R., Graus-Porta, D., Maurer, F. G., & Hynes, N. E. (1997) · PubMed · Cited by 115
Bacus, S. S., Gudkov, A. V., Zelnick, C. R., Chin, D., Stern, R. K., Stancovski, I., Peles, E., Ben-Baruch, N. E., Farbstein, H., & Lupu, R. (1993) · PubMed · Cited by 106
Ignatoski, K. M. W., Maehama, T., Markwart, S. M., Dixon, J. E., Livant, D. L., & Ethier, S. P. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.0979 · Cited by 95
Duan, C., Liimatta, M. B., & Bottum, O. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.52.37147 · Cited by 92
Hiyama, H., Iavarone, A., LaBaer, J., & Reeves, S. A. (1997) · Oncogene · doi:10.1038/sj.onc.1201080 · Cited by 91
Bacus, S. S., Zelnick, C. R., Plowman, G. D., & Yarden, Y. (1994) · PubMed · Cited by 85
Ram, T. G., & Ethier, S. P. (1996) · PubMed · Cited by 73
Heregulin Regulation of Akt/Protein Kinase B in Breast Cancer Cells
Liu, W., Li, J., & Roth, R. A. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1144 · Cited by 70
Hijazi, M., Thompson, E. W., Tang, C., Coopman, P. J., Torri, J. A., Yang, D. C. H., Mueller, S. C., & Lupu, R. (2000) · International Journal of Oncology · doi:10.3892/ijo.17.4.629 · Cited by 69
Boyer, C., Xu, F. J., Mills, G., O'Briant, K. C., Bast, R. C., Jr., Whitaker, R., Stack, S., & Yu, Y. H. (2022) · PubMed · doi:10.7274/24742149 · Cited by 66
GnRH receptor and apoptotic signaling
Imai, A., & Tamaya, T. (2000) · Vitamins and hormones · doi:10.1016/s0083-6729(00)59002-5 · Cited by 61
Sable, C. L., Filippa, N., Filloux, C., Hemmings, B. A., & OBBERGHEN, E. V. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.45.29600 · Cited by 59
Tan, M., Grijalva, R., & Yu, D. (1999) · PubMed · Cited by 59
Cited by
Feng, Y., Spezia, M., Huang, S., Yuan, C., Zeng, Z., Zhang, L., Ji, X., Liu, W., Huang, B., Luo, W., et al. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.05.001 · Cited by 1,486
PI3K-Akt pathway: Its functions and alterations in human cancer
Osaki, M., Oshimura, M., & Ito, H. (2004) · Apoptosis · doi:10.1023/b:appt.0000045801.15585.dd · Cited by 1,264
Akt signalling in health and disease
Hers, I., Vincent, E. E., & Tavaré, J. M. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.05.004 · Cited by 1,239
Activation of AKT Kinases in Cancer: Implications for Therapeutic Targeting
(2005) · Advances in Cancer Research · doi:10.1016/s0065-230x(05)94002-5 · Cited by 823
Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations
LoPiccolo, J., Blumenthal, G. M., Bernstein, W. B., & Dennis, P. A. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2007.11.003 · Cited by 801
Metadata
- Authors
- and members of the Southeast Sweden Breast Cancer Group, Pérez-Tenorio, G., & Stål, O.
- Venue
- British Journal of Cancer
- Published
- 2002-02
- Volume
- 86
- Issue
- 4
- Pages
- 540-545
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2029882446
- Cited by
- 394
- References
- 39
- FWCI
- 8.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.